Laurus Labs receives EIR from USFDA for Visakhapatnam units

Drug firm Laurus Labs on Thursday said it has received an establishment inspection report from the US health regulator for two of its active pharmaceutical ingredients units at Visakhapatnam in Andhra Pradesh. The establishment inspection report (EIR) from US Food and Drug Administration (USFDA) is for company's active pharmaceutical ingredients units 1 and 3, at Visakhapatnam, for the inspection conducted in June 2019, Laurus Labs said in a filing to BSE.

The company has also received approval from the Global Fund (GF) expert review panel for its fixed dose combination, TLE 400, for supply in GF-funded projects, it added. Laurus Labs is one among the three companies to receive the approval for this product in antiretroviral therapy, the company said.

TLE 400 is the alternative first line regimen for treatment of HIV/AIDS as per the World Health Organization guidelines issued in July 2019, it added. Shares of Laurus Labs were trading at Rs 330.95 per scrip on BSE, up 1.36 per cent from its previous close.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)